Since then, Odyssey has had no problems bringing in the megarounds. As well as the $218 million that the company launched ...

Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data ...

The calling card of Alzheimer’s disease is a buildup of misfolded amyloid protein in the brain, but many medicines struggle to penetrate the barrier protecting the mind from outside interference. A ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Roche is set to pay out $750 million upfront to acquire digital pathology specialist Path AI in a move by the pharma giant to accelerate the use of artificial intelligence in diagnostic algorithms.

Banyan BioInnovations is debuting with more than $100 million aimed at developing independent companies for promising clinical-stage treatments, plus a partnership with global contract research ...

A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...

Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...

Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an ...

From shrinking drug development timelines to scouting potential acquisitions, the recent run of first-quarter earnings results marked a shift for Big Pharma from AI hype to explaining how the ...

BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis ...

For people living with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), the only treatment option is a regimen that can include up to 40 pills a day. With a $250 million investment ...